The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | N | Nervous system | |
| 2 | N02 | Analgesics | |
| 3 | N02B | Other analgesics and antipyretics | |
| 4 | N02BF | Gabapentinoids | |
| 5 | N02BF01 | Gabapentin |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 1.8 g |
| Active Ingredient | Description | |
|---|---|---|
| Gabapentin |
Gabapentin readily enters the brain and prevents seizures in a number of animal models of epilepsy. Gabapentin binds with high affinity to the α2δ (alpha-2-delta) subunit of voltage-gated calcium channels and it is proposed that binding to the α2δ subunit may be involved in gabapentin’s anti-seizure effects in animals. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| GABACOR Capsule, hard | Pharmaceutical Benefits Scheme (AU) | MPI, EU: SmPC | |
| GABENIL Hard capsule | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
| NEURONTIN Capsule / Film-coated tablet / Solution | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| NEURONTIN Capsule, hard | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
